NantHealth Presented Clinical Data on Immunotherapy, Molecularly Targeted Agents and Tumor Biology at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

CULVER CITY, Calif.–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced the publication of four abstracts on developmental therapeutics for immunotherapy, molecularly targeted agents and tumor biology during the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. The program, held virtually from May 29-31, 2020, gathered oncology physicians, biotechnology executives, researchers, patient advocat